Background: Vaginal discharge is one of most common and nagging problems that women face. About 20% - 25% of women who visit gynecology department complain of vaginal discharge and leucorrhoea. An orally administered ...Background: Vaginal discharge is one of most common and nagging problems that women face. About 20% - 25% of women who visit gynecology department complain of vaginal discharge and leucorrhoea. An orally administered combination kit, containing 2 g secnidazole, 1 g azithromycin and 150 mg fluconazole (Azimyn FS Kit), has been successfully evaluated in clinical trials and used in several countries for management syndromic vaginal discharge due to infections. Methods: This is a longitudinal study which aimed to verify the clinical efficacy of the combined oral kit containing secnidazole, azithromycin and fluconazole (Azimyn FS Kit<sup><sup>®</sup></sup>) in the syndromic treatment of abnormal vaginal discharge in patients received in outpatient consultations in Kinshasa/DR Congo from March to September 2023. Results: Majority of patients had whitish vaginal discharge (51.6%) of average abundance (56.2%), accompanied by pruritus in 72.1% of cases, and dyspareunia in 23.5% of cases and hypogastralgia in 40.2% of cases. One week after treatment with the Azimyn FS<sup><sup>®</sup></sup> combined kit, at the greatest majority of patients (97.3%), abnormal vaginal discharge had decreased by more than 50% (84.1%). Two weeks after treatment with the Azimyn FS<sup><sup>®</sup></sup> combined kit, almost all patients (97.3%) no longer had abnormal vaginal discharge which had completely disappeared. Conclusion: A single dose of secnidazole, azithromycin and fluconazole in the form of an oral combi-kit (Azimyn FS Kit) has shown excellent therapeutic effectiveness in the syndromic treatment of abnormal vaginal discharge wherein patients were treated without diagnostic confirmation.展开更多
<strong>Background:</strong><span style="font-family:;" "=""><span> Oral iron supplements, usually in the form of ferrous salts, are associated with gastric side effect...<strong>Background:</strong><span style="font-family:;" "=""><span> Oral iron supplements, usually in the form of ferrous salts, are associated with gastric side effects, poor compliance and failure of anemia treatment. To make iron more bioavailable, reduce the gastric side effects and increase the patient compliance, newer iron form, Ferric Sodium EDTA, has become available on the market. </span><b><span>Objective:</span></b><span> To assess the change in hemog</span><span>lobin level after iron supplementation with Ferric Sodium EDTA during </span><span>pregnancy. </span><b><span>Materials and Methods:</span></b><span> This is a longitudinal study concerning 337 </span><span>women attending antenatal care in maternity hospitals in the Democratic</span> <span>Republic of Congo from May to December 2020. The study included soci</span><span>odemographic and anthropometric variables along with type of feed, hemoglobin </span><span>level at recruitment and after three weeks of taking iron supplement with</span><span> Ferric Sodium EDTA (Hemoforce Plus Zinc</span></span><sup><span><span><sup></span><span>®</span><span></sup></span></span></sup><span style="font-family:;" "=""><span> syrup). For statistical analysis, we used t-test or ANOVA and chi-square test, the significance being stated at p < 0.05. </span><b><span>Results:</span></b><span> The frequency of pregnancy anemia was 51.4%. The mean </span><span>hemoglobin value of the overall study group was 8.7 ± 0.5 g/dL. The mean</span><span> maternal age and weight were 28.9 ± 6.2 years and 65.3 ± 11.7 kg, respectively. Most pregnant women (83.1%) had a diet consisting of food of plant and animal origin in equal proportions. Mean of Body Mass Index (BMI) was 24.6 ± 4.6 Kg/m</span><sup><span>2</span></sup><span> and 44.3% were overweight and obese. The co-morbidities associated were malaria and intestinal parasitosis found in 45% and 5.9% of cases, </span><span>respectively. After iron treatment with Ferric Sodium EDTA, the average</span><span> hemoglobin l展开更多
文摘Background: Vaginal discharge is one of most common and nagging problems that women face. About 20% - 25% of women who visit gynecology department complain of vaginal discharge and leucorrhoea. An orally administered combination kit, containing 2 g secnidazole, 1 g azithromycin and 150 mg fluconazole (Azimyn FS Kit), has been successfully evaluated in clinical trials and used in several countries for management syndromic vaginal discharge due to infections. Methods: This is a longitudinal study which aimed to verify the clinical efficacy of the combined oral kit containing secnidazole, azithromycin and fluconazole (Azimyn FS Kit<sup><sup>®</sup></sup>) in the syndromic treatment of abnormal vaginal discharge in patients received in outpatient consultations in Kinshasa/DR Congo from March to September 2023. Results: Majority of patients had whitish vaginal discharge (51.6%) of average abundance (56.2%), accompanied by pruritus in 72.1% of cases, and dyspareunia in 23.5% of cases and hypogastralgia in 40.2% of cases. One week after treatment with the Azimyn FS<sup><sup>®</sup></sup> combined kit, at the greatest majority of patients (97.3%), abnormal vaginal discharge had decreased by more than 50% (84.1%). Two weeks after treatment with the Azimyn FS<sup><sup>®</sup></sup> combined kit, almost all patients (97.3%) no longer had abnormal vaginal discharge which had completely disappeared. Conclusion: A single dose of secnidazole, azithromycin and fluconazole in the form of an oral combi-kit (Azimyn FS Kit) has shown excellent therapeutic effectiveness in the syndromic treatment of abnormal vaginal discharge wherein patients were treated without diagnostic confirmation.
文摘<strong>Background:</strong><span style="font-family:;" "=""><span> Oral iron supplements, usually in the form of ferrous salts, are associated with gastric side effects, poor compliance and failure of anemia treatment. To make iron more bioavailable, reduce the gastric side effects and increase the patient compliance, newer iron form, Ferric Sodium EDTA, has become available on the market. </span><b><span>Objective:</span></b><span> To assess the change in hemog</span><span>lobin level after iron supplementation with Ferric Sodium EDTA during </span><span>pregnancy. </span><b><span>Materials and Methods:</span></b><span> This is a longitudinal study concerning 337 </span><span>women attending antenatal care in maternity hospitals in the Democratic</span> <span>Republic of Congo from May to December 2020. The study included soci</span><span>odemographic and anthropometric variables along with type of feed, hemoglobin </span><span>level at recruitment and after three weeks of taking iron supplement with</span><span> Ferric Sodium EDTA (Hemoforce Plus Zinc</span></span><sup><span><span><sup></span><span>®</span><span></sup></span></span></sup><span style="font-family:;" "=""><span> syrup). For statistical analysis, we used t-test or ANOVA and chi-square test, the significance being stated at p < 0.05. </span><b><span>Results:</span></b><span> The frequency of pregnancy anemia was 51.4%. The mean </span><span>hemoglobin value of the overall study group was 8.7 ± 0.5 g/dL. The mean</span><span> maternal age and weight were 28.9 ± 6.2 years and 65.3 ± 11.7 kg, respectively. Most pregnant women (83.1%) had a diet consisting of food of plant and animal origin in equal proportions. Mean of Body Mass Index (BMI) was 24.6 ± 4.6 Kg/m</span><sup><span>2</span></sup><span> and 44.3% were overweight and obese. The co-morbidities associated were malaria and intestinal parasitosis found in 45% and 5.9% of cases, </span><span>respectively. After iron treatment with Ferric Sodium EDTA, the average</span><span> hemoglobin l
